EMA has 'not yet reached conclusion' on AstraZeneca

coronavirus vaccine
Credit: Pixabay/CC0 Public Domain

The EU's drug regulator said Tuesday it is still deciding whether the AstraZeneca coronavirus vaccine causes blood clots, after one top official said there was a clear link.

The European Medicines Agency's safety committee "has not yet reached a conclusion and the review is currently ongoing", the Amsterdam-based EMA said in a statement to AFP.

"We will communicate and hold a press briefing as soon as the review is finalised. This is currently expected tomorrow (Wednesday, 7 April) or on Thursday, 8 April," it added.

EU Health Commissioner Stella Kyriakides later said that the agency was expected to make its decision "late Wednesday", adding that she was in "close contact" with the EMA.

The statement came after the EMA's head of vaccine strategy Marco Cavaleri was quoted in Italian media as saying that there was a "clear" connection and that the agency would announce it within hours.

"In my opinion, we can say it now, it is clear there is a link with the vaccine," Cavaleri told Italy's Il Messaggero newspaper in an interview. "But we still do not know what causes this reaction."

After several countries suspended the use of the AstraZeneca jab, the EMA said on March 18 that the benefits of using it outweighed the risks and it should remain in use.

But it has said there is a possible link to rare blood clots and that it would issue updated advice during this week's meeting of its safety committee.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

© 2021 AFP

Citation: EMA has 'not yet reached conclusion' on AstraZeneca (2021, April 6) retrieved 19 April 2021 from https://medicalxpress.com/news/2021-04-ema-links-astrazeneca-vaccine-thrombosis.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
781 shares

Feedback to editors

User comments